Subscribe To
Rapt therapeutics: potential strong upside ahead
RAPT Therapeutics, Inc. is a clinical-stage biotech developer of specific small molecules that can modulate the critical immune drivers of inflammator...
March 30, 2023, 12:12 am
Rapt therapeutics presents update from its phase 1/2 clinical trial for flx475 as monotherapy and in combination with pembrolizumab in patients with advanced cancer
Data Presented at ESMO Immuno-Oncology Congress SOUTH SAN FRANCISCO, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT)...
December 8, 2022, 11:30 am
Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...
December 1, 2022, 12:05 am
Rapt therapeutics to present flx475 phase 1/2 data at the european society for medical oncology (esmo) immuno-oncology annual congress
SOUTH SAN FRANCISCO, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-s...
November 30, 2022, 7:05 pm